Evidence map›Paper›PMID 35267421›Full record

ArticleCancers2022

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia.

Abel Tesfaye Anshabo, Laychiluh Bantie, Sarah Diab, Jimma Lenjisa, Alemwork Kebede, Yi Long, Gary Heinemann, Jasmine Karanjia, Benjamin Noll, Sunita K C Basnet and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Abel Tesfaye AnshaboDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-8671-0024
Laychiluh BantieDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Sarah DiabDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Jimma LenjisaDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Alemwork KebedeDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Yi LongDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Gary HeinemannDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0001-9513-181X
Jasmine KaranjiaDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Benjamin NollDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Sunita K C BasnetDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Manjun LiDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-5296-7614
Robert MilneDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.
Hugo AlbrechtDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-3951-1866
Shudong WangDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0001-6225-5525
University of South Australia · AU

Funding

Aucentra Therapeutics Pty Ltd. Small molecule kinase inhibitors for cancer therapy
6 · The paper itself

Abstract

Mutations in FMS-like tyrosine kinase 3 (FLT3) occur in approximately one-third of AML patients and are associated with a particularly poor prognosis. The most common mutation, FLT3-ITD, is a self-activating internal tandem duplication (ITD) in the FLT3 juxtamembrane domain. Many FLT3 inhibitors have shown encouraging results in clinical trials, but the rapid emergence of resistance has severely limited sustainable efficacy. Co-targeting of CDK9 and FLT3 is a promising two-pronged strategy to overcome resistance as the former plays a role in the transcription of cancer cell-survival genes. Most prominently, MCL-1 is known to be associated with AML tumorigenesis and drug resistance and can be down-regulated by CDK9 inhibition. We have developed CDDD11-8 as a potent CDK9 inhibitor co-targeting FLT3-ITD with

Indexed as

cancerCDK9FLT3leukemiatargeted therapy

Identifiers

PMID35267421
PMCPMC8909834
OpenAlexW4212912230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.